PE-22-28 (Spadin): Research Guide & Chemical Profile

PE-22-28 (Spadin) is a linear heptapeptide with the amino acid sequence WRLEQGP (Trp-Arg-Leu-Glu-Gln-Gly-Pro), derived from the propeptide region of the neurotensin receptor 3/sortilin precursor protein. The peptide corresponds to residues 22–28 of the sortilin propeptide (PE), hence the designation PE-22-28. It has a molecular formula of C₃₉H₅₈N₁₀O₁₁ and a molecular weight of approximately 854.9 Da. The compound was first identified and characterized by Mazella and colleagues at IPMC-CNRS in Valbonne, France [1].

The peptide features a tryptophan residue at the N-terminus providing intrinsic fluorescence properties and a C-terminal proline residue that confers resistance to certain carboxypeptidases. The internal arginine and glutamic acid residues contribute to the molecule's amphipathic character, while the overall sequence adopts a relatively flexible conformation in solution as determined by circular dichroism spectroscopy. The Gly-Pro C-terminal motif is characteristic of a type II beta-turn structural element.

Synthetic PE-22-28 is produced by solid-phase peptide synthesis using Fmoc chemistry, yielding a white to off-white powder upon lyophilization. Typical research-grade specifications require ≥95% purity by reversed-phase HPLC with identity confirmation by ESI-MS or MALDI-TOF mass spectrometry.

• Sequence: WRLEQGP (Trp-Arg-Leu-Glu-Gln-Gly-Pro)
• Molecular formula: C₃₉H₅₈N₁₀O₁₁
• Molecular weight: ~854.9 Da
• Origin: Sortilin propeptide residues 22–28
• Target: TREK-1 two-pore-domain potassium channel
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water, DMSO, PBS
• Storage: –20°C desiccated, protected from light

TREK-1 (TWIK-related K⁺ channel 1, gene name KCNK2) belongs to the two-pore-domain potassium (K2P) channel family, which produces background or leak potassium currents that regulate neuronal resting membrane potential and excitability. TREK-1 is broadly expressed throughout the central nervous system with particularly high density in the hippocampus, prefrontal cortex, hypothalamus, and dorsal raphe nucleus—brain regions critically involved in mood regulation and stress response [2].

The channel functions as a homodimer, with each subunit containing four transmembrane domains and two pore-forming loops. TREK-1 is mechanosensitive and polymodal, responding to membrane stretch, intracellular acidification, temperature changes, polyunsaturated fatty acids (arachidonic acid), and volatile anesthetics. This polymodal regulation positions TREK-1 as an integrator of multiple physiological signals affecting neuronal excitability.

Genetic studies provided the first evidence linking TREK-1 to mood regulation. TREK-1 knockout mice (kcnk2⁻/⁻) display a depression-resistant phenotype in the forced swim test, tail suspension test, and conditioned suppression of motility paradigm, phenocopying the effects of chronic antidepressant treatment [3]. This genetic evidence established TREK-1 as a validated target for antidepressant drug discovery and motivated the search for selective channel blockers.

PE-22-28 blocks TREK-1 channel activity by binding to an extracellular site on the channel complex. Electrophysiological studies using whole-cell patch-clamp recordings in HEK-293 cells expressing recombinant TREK-1 channels demonstrated that PE-22-28 inhibits TREK-1 currents with an IC₅₀ in the low nanomolar range [1]. The blockade is reversible upon peptide washout, indicating a non-covalent binding mechanism.

By blocking TREK-1 background potassium conductance, PE-22-28 increases neuronal excitability in TREK-1-expressing neurons. This depolarizing effect enhances serotonergic neuron firing in the dorsal raphe nucleus, increases serotonin release in projection areas (hippocampus, prefrontal cortex), and downstream activates 5-HT receptor-mediated signaling cascades associated with antidepressant responses [4]. The mechanism parallels the net effect of SSRIs on serotonergic transmission but operates through a fundamentally different molecular target.

Selectivity profiling has shown that PE-22-28 has minimal activity against other K2P family members (TREK-2, TRAAK, TASK-1, TASK-3) at concentrations that fully block TREK-1, indicating good pharmacological selectivity within the two-pore-domain channel family. This selectivity profile is important for attributing observed behavioral effects specifically to TREK-1 blockade rather than to non-specific modulation of neuronal excitability.

PE-22-28 has been tested in multiple rodent behavioral models of depression and anxiety. In the forced swim test (FST), a widely used preclinical screen for antidepressant activity, PE-22-28 administered intraperitoneally at doses of 100 µg/kg to 1 mg/kg significantly reduced immobility time compared to vehicle controls [1]. Critically, this antidepressant-like effect emerged within 4 days of treatment initiation, in contrast to the 14–21 day delay typically required for SSRI-class compounds (fluoxetine, paroxetine) in the same paradigm.

In the novelty-suppressed feeding test, a model with predictive validity for anxiolytic and antidepressant effects requiring chronic treatment, PE-22-28 reduced the latency to feed after only 4 days of treatment. This rapid onset was comparable to ketamine (which acts within hours) and significantly faster than fluoxetine (which requires 21+ days in this paradigm) [5]. The tail suspension test and splash test further confirmed the antidepressant-like behavioral profile across multiple behavioral dimensions.

In the corticosterone-induced model of depression, where chronic corticosterone administration produces depressive-like behaviors and hippocampal atrophy, PE-22-28 reversed behavioral deficits and restored hippocampal neurogenesis markers. These findings extend the compound's activity profile beyond acute behavioral screens to a chronic stress-relevant model of depression.

One of the most significant findings in PE-22-28 research is its robust stimulation of hippocampal neurogenesis. Studies using BrdU incorporation and doublecortin (DCX) immunostaining in adult mice demonstrated that PE-22-28 treatment (4 days, i.p.) increased the number of proliferating neural progenitor cells and immature neurons in the subgranular zone (SGZ) of the dentate gyrus by approximately 50–70% compared to vehicle controls [5]. This neurogenic effect is comparable in magnitude to chronic fluoxetine treatment but achieved in a fraction of the treatment duration.

The neurogenic action of PE-22-28 is associated with upregulation of brain-derived neurotrophic factor (BDNF) in the hippocampus. BDNF is a key trophic factor supporting neuronal survival, synaptic plasticity, and adult neurogenesis, and its downregulation is consistently observed in depression models and post-mortem brain tissue from depressed individuals. PE-22-28 treatment increases both BDNF mRNA expression and mature BDNF protein levels in the hippocampal formation [6].

The connection between TREK-1 blockade and BDNF upregulation likely involves enhanced serotonergic signaling through 5-HT₁A and 5-HT₄ receptors on hippocampal neurons, which are known to activate CREB-dependent BDNF transcription. This places PE-22-28 within the broader neuroplasticity hypothesis of antidepressant action, where restoration of impaired neurogenesis and synaptic plasticity is considered a key mechanism underlying therapeutic efficacy.

The rapid onset of PE-22-28's antidepressant-like effects (4 days vs. 21+ days for SSRIs) represents a critical differentiating feature with potential translational significance. Classical monoamine-based antidepressants require weeks of chronic administration to produce therapeutic effects, a delay attributed to the need for 5-HT₁A autoreceptor desensitization and downstream neuroplastic adaptations. PE-22-28 appears to bypass this rate-limiting step by directly enhancing serotonergic neuron firing through TREK-1 blockade.

The rapid-acting profile of PE-22-28 places it in a category alongside ketamine and other novel antidepressant mechanisms that engage neuroplasticity pathways more directly. However, unlike ketamine (which acts through NMDA receptor blockade and has abuse potential and dissociative side effects), PE-22-28 operates through a potassium channel mechanism without reported psychotomimetic or addictive properties in preclinical studies [7].

Research comparing the time course of neurochemical adaptations induced by PE-22-28 vs. fluoxetine has revealed that PE-22-28 produces more rapid desensitization of 5-HT₁A autoreceptors in the dorsal raphe and faster enhancement of hippocampal 5-HT neurotransmission, providing a mechanistic basis for the accelerated behavioral response.

As a heptapeptide, PE-22-28 faces pharmacokinetic challenges common to peptide therapeutics, including susceptibility to proteolytic degradation and limited oral bioavailability. In the published preclinical studies, PE-22-28 has been administered primarily via intraperitoneal injection, with effective doses in the range of 100 µg/kg to 1 mg/kg in mice.

Evidence for central nervous system penetration comes from the robust behavioral and neurochemical effects observed following peripheral (i.p.) administration, suggesting sufficient blood-brain barrier crossing to engage central TREK-1 channels. Direct measurement of brain PE-22-28 concentrations following systemic administration has not been extensively reported, though the observed pharmacological effects are consistent with central target engagement.

Efforts to improve the pharmacokinetic profile of PE-22-28 have led to the development of analogs with enhanced stability and potency, including N-methylated derivatives and retro-inverso peptide variants. These structure-activity relationship studies represent an active area of medicinal chemistry optimization aimed at translating the preclinical findings toward potential therapeutic development.

Systematic structure-activity relationship (SAR) studies on the PE-22-28 sequence have identified key residues required for TREK-1 blocking activity. The N-terminal tryptophan (W22) and arginine (R23) residues are critical for channel binding, with alanine substitution at either position substantially reducing inhibitory potency. The C-terminal proline (P28) contributes to conformational constraint but is more tolerant of substitution [8].

Truncation studies have shown that the full heptapeptide sequence is required for optimal TREK-1 blockade, with shorter fragments (PE-22-25, PE-25-28) showing reduced potency. Extension of the sequence beyond residue 28 does not improve activity, confirming that the 22–28 segment contains the minimal pharmacophore for TREK-1 interaction.

Second-generation analogs have explored modifications to improve metabolic stability and brain penetration. These include N-methylation of backbone amide bonds to resist proteolysis, introduction of unnatural amino acids at susceptible cleavage sites, and PEGylation strategies to extend plasma half-life. Several of these optimized analogs retain TREK-1 blocking activity while demonstrating improved pharmacokinetic profiles in preclinical evaluation.

Preclinical safety evaluation of PE-22-28 has been conducted as part of the published research program. In standard safety pharmacology assessments, PE-22-28 at antidepressant-effective doses did not produce significant effects on locomotor activity (ruling out psychostimulant-like confounds in behavioral tests), motor coordination (rotarod), or baseline anxiety measures (elevated plus maze at sub-anxiolytic doses) [1].

The selectivity of PE-22-28 for TREK-1 over other ion channel targets has been characterized in electrophysiological screening panels. Beyond K2P channel selectivity, the compound has been tested against voltage-gated sodium and calcium channels, with no significant blocking activity observed at concentrations up to 10 µM. This ion channel selectivity profile suggests a low risk of cardiac safety issues (QT prolongation) that complicate many CNS drug candidates.

Researchers working with PE-22-28 should be aware of its potent biological activity at nanomolar concentrations and should follow appropriate handling protocols including protective equipment and containment measures. Storage should be at –20°C in lyophilized form, with reconstituted solutions used within 14 days when stored at 2–8°C.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism